CA3236861A1 - Pi3k-alpha inhibitors and methods of making and using the same - Google Patents

Pi3k-alpha inhibitors and methods of making and using the same Download PDF

Info

Publication number
CA3236861A1
CA3236861A1 CA3236861A CA3236861A CA3236861A1 CA 3236861 A1 CA3236861 A1 CA 3236861A1 CA 3236861 A CA3236861 A CA 3236861A CA 3236861 A CA3236861 A CA 3236861A CA 3236861 A1 CA3236861 A1 CA 3236861A1
Authority
CA
Canada
Prior art keywords
compound
solid
formula
crystalline
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3236861A
Other languages
English (en)
French (fr)
Inventor
Andre Lescarbeau
Alessandro Boezio
Surendra P. Singh
Qinglin Che
Siyi Jiang
Hongyan He
Qiuxiang ZHOU
Jiajia Zhou
Yuan Lin
Wei Gu
Min Lu
Yunfei Zhou
Xijian GONG
Jiahui Chen
Xiaohong Wang
Changbo YIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Relay Therapeutics Inc
Original Assignee
Relay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Relay Therapeutics Inc filed Critical Relay Therapeutics Inc
Publication of CA3236861A1 publication Critical patent/CA3236861A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3236861A 2021-11-03 2022-11-03 Pi3k-alpha inhibitors and methods of making and using the same Pending CA3236861A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163263474P 2021-11-03 2021-11-03
CNPCT/CN2021/128533 2021-11-03
US63/263,474 2021-11-03
CN2021128533 2021-11-03
PCT/US2022/079221 WO2023081757A1 (en) 2021-11-03 2022-11-03 Pi3k-alpha inhibitors and methods of making and using the same

Publications (1)

Publication Number Publication Date
CA3236861A1 true CA3236861A1 (en) 2023-05-11

Family

ID=86242193

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3236861A Pending CA3236861A1 (en) 2021-11-03 2022-11-03 Pi3k-alpha inhibitors and methods of making and using the same

Country Status (13)

Country Link
US (1) US20260125374A1 (enExample)
EP (1) EP4426314A4 (enExample)
JP (1) JP2024540303A (enExample)
KR (1) KR20240112283A (enExample)
CN (1) CN118401245A (enExample)
AU (1) AU2022381187A1 (enExample)
CA (1) CA3236861A1 (enExample)
CL (1) CL2024001364A1 (enExample)
IL (1) IL312466A (enExample)
MX (1) MX2024005429A (enExample)
PE (1) PE20250676A1 (enExample)
TW (1) TW202334136A (enExample)
WO (1) WO2023081757A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021263914B2 (en) 2020-04-29 2026-07-23 D.E. Shaw Research, Llc PI3K-α inhibitors and methods of use thereof
WO2024055992A1 (zh) * 2022-09-14 2024-03-21 南京再明医药有限公司 三环化合物及其应用
JP2025538147A (ja) 2022-11-02 2025-11-26 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化
WO2024233256A1 (en) 2023-05-05 2024-11-14 Eli Lilly And Company Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
JP6472803B2 (ja) * 2013-09-05 2019-02-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリアゾロピリジン化合物、その組成物及び使用方法
WO2017000277A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
EP3931188B1 (en) * 2019-02-26 2023-08-30 Boehringer Ingelheim International GmbH New isoindolinone substituted indoles and derivatives as ras inhibitors
AU2021263914B2 (en) * 2020-04-29 2026-07-23 D.E. Shaw Research, Llc PI3K-α inhibitors and methods of use thereof

Also Published As

Publication number Publication date
CL2024001364A1 (es) 2024-10-25
KR20240112283A (ko) 2024-07-18
EP4426314A1 (en) 2024-09-11
IL312466A (en) 2024-06-01
MX2024005429A (es) 2024-05-21
CN118401245A (zh) 2024-07-26
JP2024540303A (ja) 2024-10-31
EP4426314A4 (en) 2025-10-01
US20260125374A1 (en) 2026-05-07
PE20250676A1 (es) 2025-03-04
AU2022381187A1 (en) 2024-05-16
TW202334136A (zh) 2023-09-01
WO2023081757A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
AU2020343681B2 (en) Heterocyclic RIP1 kinase inhibitors
US20260125374A1 (en) Pi3k-alpha inhibitors and methods of making and using the same
JP2023529908A (ja) Ｂｒｍ標的化化合物及び関連する使用方法
JP2023022225A (ja) Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
IL302913A (en) FGFR inhibitors and methods for their preparation and use
JP2021514982A (ja) インドール−２−カルボニル化合物及びｂ型肝炎治療のためのそれらの使用
WO2019189732A1 (ja) 光学活性な架橋型環状２級アミン誘導体
CN118201896A (zh) PI3K-α抑制剂和其使用方法
JP6965390B2 (ja) フマレート類似体および自己免疫疾患または炎症性疾患の治療におけるその使用
EP4426286A1 (en) Bifunctional pi3k-alpha inhibitors and uses thereof
CA3239771A1 (en) Modulators of rho-associated protein kinase (rock)
TW202527954A (zh) PI3Kα抑制劑及其製造與使用方法
WO2024151930A1 (en) Pi3k inhibitors and methods of making and using the same
CN118251217A (zh) PI3Kα抑制剂及其使用方法
EA051309B1 (ru) Ингибиторы pi3k-альфа и способы их получения и использования
WO2025217141A1 (en) Pharmaceutical compounds and compositions as modulators of mas-related g-protein receptor x2
CA3154862A1 (en) Shp2 phosphatase inhibitors and methods of making and using the same
NZ743251A (en) Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241025

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241031

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20250721

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251024

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260525

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260525